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INTRODUCTION
The microbiome refers to a community of microbes and the 
collection of genes contained within these microbes. Microbi-
al cells are as abundant as somatic cells and have many more 
genes than the human genome (1.3:1 cells, 100:1 genes) [1]. 
The microbiome is affected by several factors, including hu-
man genetics, immune responses, diet, antibiotics, body part, 
lifestyle, and geography [2]. The microbiome is also thought to 
control gastrointestinal (GI) physiology, metabolism, nutri-
tion, brain function, immune function, and even behavior [3]. 
Furthermore, the human microbiome is known to be corre-
lated with diseases including cancer, obesity, irritable bowel 
disease, arthritis, and various psychiatric and neurological 
conditions such as major depressive disorder, stroke, Parkin-
son’s disease, Alzheimer’s disease, and autism [4]. However, we 
do not yet understand how variations in the microbiome af-
fect health and disease. Furthermore, the mechanism and ex-
tent to which the gut microbiota and treatments based on the 
microbiome (prebiotic, probiotic, and dietary interventions) 
influence brain health and behavior are not yet clearly known 
[5]. The microbiota–gut–brain axis, which refers to the bidi-
rectional communication pathway between gut bacteria and 
the central nervous system (CNS), has important effects on 
many processes in the brain. These processes include neuro-
inflammation; stress axes activation; neurotransmission; for-
mation of the blood-brain-barrier; myelination; neurogenesis 
and microglia maturation; synthesis of neurotransmitters in-
cluding gamma-amino-butyric acid (GABA), noradrenalin, 
and dopamine; and modulation of complex behaviors such as 
sociability and anxiety [5,6]. 
Several studies have demonstrated that the gut microbiota 
actually affects the development of the nervous system. For 
example, one study showed that neurogenesis in the dorsal 
hippocampus of adult germ-free (GF) mice was higher than 
that in conventional mice [7]. These results are consistent 
with the findings that neurogenesis of the hippocampus and 
the number of monocytes are reduced in mice treated with 
antibiotics over a long period [8]. Additionally, the blood–
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brain barrier (BBB) is more permeable without the gut mi-
crobiota, allowing macromolecules to enter the brain. This 
has been reported to be the result of reduced expression of the 
proteins that comprise the tight junction of the brain endo-
thelium. The reduced BBB permeability after re-colonization 
with gut microbiota is clear evidence that the gut microbiota 
is involved in brain development [9]. Thus, it is rational to 
suggest that gut bacteria play a role in neurological and psy-
chiatric diseases such as autism spectrum disorder (ASD). 
ASD constitutes a group of neurodevelopmental disorders, 
which is characterized by repetitive and stereotyped behavior, 
with impaired communication and social interaction [10]. 
ASD has a profound effect on the development of children 
and on society. In 2014, the overall prevalence of ASD was 
16.8 per 1,000 children aged 8 years, and in boys the preva-
lence was much higher (26.6 per 1,000 children) than in girls 
(6.6 per 1,000 children) [11]. The current cost of supporting a 
child with ASD without intellectual impairment is £0.92 mil-
lion in the United Kingdom and $1.4 million in the United 
States. The main costs of caring for children with ASD are 
derived from their need for special education and treatment, 
as well as the resultant reduced parental productivity [12]. Ac-
cordingly, there have been a number of efforts to identify bio-
markers associated with ASD, including those related to ge-
netic causes, immune system abnormalities, inflammation, 
and exposure to environmental toxic substances. Despite 
growing evidence that endogenous markers are involved in 
the pathology of ASD, early detection of these disorders re-
mains a major challenge [13]. In addition, there are currently 
no effective treatments for the core symptoms of ASD, in-
cluding social skill deficits. Therefore, understanding the role 
of microbiota and modulating the microbiota-gut-brain axis 
could help identify new ways to treat ASD [14].
Indeed, studies suggesting a correlation between multiple 
aspects of ASD and gut microbiota have been reported. In 
this article, we reviewed the results of studies investigating 
changes in the gut microbiota and their role in ASD. Our aim 
was to assess the value of microbiota as a potential biomarker 
or therapeutic target for ASD.
GI DISTURBANCE AS A COMMON 
COMORBIDITY OF ASD
The theory of the connection between ASD and the gut 
microbiota originated from GI symptoms that are frequently 
identified early in children with ASD. The GI impairments 
that are commonly observed in patients with ASD [15] in-
clude overproduction of intestinal gasses/flatulence, bloat-
ing, abdominal pain, diarrhea, burping/belching, gastro-
esophageal reflux symptoms, and constipation [16]. Different 
studies have reported that the prevalence of GI disorders in 
individuals with ASD ranges from 9% to 84%, depending on 
the assessment method, compared with 9% to 37% for chil-
dren without ASD [17,18]. General GI symptoms are report-
ed to be five times more common in children with ASD; ab-
dominal pain is twice as frequent, and both constipation and 
diarrhea have a four times higher incidence than that ob-
served in typically developing children. The subjective 
symptoms of GI disorders such as abdominal pain, heart-
burn, or nausea are very difficult to evaluate because the 
clinical manifestation of digestive tract diseases in children 
with ASD may differ from those in children with typical de-
velopment [17]. Functional constipation is a frequent finding 
in individuals with ASD [19]. The prevalence of constipation 
in ASD ranges from 20% to 33.9% according to recent stud-
ies [20], with findings indicating that moderate to severe 
constipation is more frequent in individuals with autism 
than in controls (36% vs. 10%) [19]. 
Several studies have reported an association between GI 
disturbances and the behavioral phenotype of ASD. GI 
symptoms have been reported to have a high incidence and 
be strongly associated with the severity of ASD [21]. ASD 
patients with GI disturbances show severe social skill defi-
cits and higher anxiety than those without GI disturbances 
[22]. Children with ASD with GI disturbances have also 
been reported to have frequent anger outbursts and aggres-
sive behavior [23]. One study indicated that such aggressive-
ness in children with ASD could be another manifestation 
of the physical discomfort caused by GI disturbances [24]. 
MECHANISM OF GI IMPAIRMENT AND 
THE GUT MICROBIOTA IN ASD 
The enteric nervous system (ENS) is a large and complex 
component of the autonomic nervous system and is uniquely 
equipped with internal microcircuits that can adjust GI func-
tion regardless of CNS input. Because the ENS and CNS 
share common neurotransmitters, signal pathways, and ana-
tomical characteristics, the pathophysiological mechanisms 
underlying CNS disease are often associated with GI symp-
toms [25]. A genetic study reported that mutations in the 
chromodomain helicase DNA-binding protein 8 (CHD8) 
gene are associated with a genetically defined ASD subtype. 
ASD patients with CHD8 mutations are typified by macro-
cephaly, distinct faces, and GI complaints due to slow transit 
constipation. Disruption of the zebrafish CHD8 orthologue 
recapitulates features of the human phenotype, including ex-
pansion of the forebrain/midbrain and impairment of GI 
motility due to a reduction in postmitotic enteric neurons 
[26]. Pitt-Hopkins syndrome, another subtype of ASD, results 
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from haploinsufficiency of the transcription factor 4 gene, 
and patients often suffer from constipation and gastroesoph-
ageal reflux [27]. Similarly, another study showed that the au-
tism-linked R451C mutation of the neuroligin-3 gene changes 
the ENS in mice [28]. Enteric glial cells (EGCs) are another 
population of cells in the ENS emerging as local GI regulators 
that participate in neuroprotection, gut motility, gut inflam-
mation, intestinal epithelial barrier function, and synaptic 
neurotransmission regulation [29]. Grubišić and Parpura [30] 
reported that EGC-linked connexin 43 plays a role in the 
mechanism contributing to GI problems, based on the altered 
expression of astrocytic markers in patients with ASD. The 
underlying mechanism of these phenomena remains elusive, 
and further studies are warranted to elucidate the involve-
ment of EGCs in the ASD process.
Another keyword describing GI symptoms seen in ASD 
patients is “inflammation.” Although no consistent results 
have been obtained, some studies have reported changes in 
inflammation markers in ASD patients with GI symptoms. 
For example, the transcriptional profile of intestinal tissue 
from children with ASD was similar to that of patients with 
inflammatory bowel diseases such as ulcerative colitis and 
Crohn’s disease [31]. In addition, infiltration of lymphocytes, 
eosinophils, and monocytes was observed in the intestinal 
tissues of ASD patients, similar to that in those with food al-
lergies [32]. 
The “leaky gut” hypothesis is based on the idea that defects 
in intestinal epithelial barrier permeability lead to inappro-
priate signaling by luminal components including bacteria, 
environmental toxins, and even dietary macromolecules. In-
creasing intestinal permeability allows the metabolites secret-
ed by bacteria to cross the barrier and enter the blood, and 
can affect the brain by promoting the secretion of cytokines 
and triggering an immune response [33]. Inflammatory cyto-
kines released by immune activation affect the CNS and in-
terfere with normal neural development early in life, which 
can lead to ASD. Compared to children with typical develop-
ment, one study found astrocyte overactivation and increased 
levels of pro-inflammatory cytokines in the cerebrospinal 
fluid (CSF) of children with ASD [34]. Another study showed 
that plasma levels of cytokines, such as interleukin, tumor 
necrosis factor-α (TNF-α), and transforming growth factor 
beta were increased in children with ASD. In particular, this 
altered immune profile was associated with the severity of 
behavioral problems in ASD [35,36]. These studies suggest 
that inflammatory processes derived from the intestines may 
play an important role in the neuronal development that is 
central to ASD, as well as in the GI symptoms.
The gut microbiota plays an important role in regulating 
epithelial integrity that affects intestinal permeabillty [37]. 
For example, decreased expression of barrier-forming pro-
teins, and increased expression of pore-forming proteins in 
tight junctions of intestinal epithelium, have been shown to 
be associated with Lactobacillus [23,38]. In children with 
ASD, concentrations of zonulin, a gut permeability modu-
lating protein, are higher than those in typically developed 
children, and increased zonulin levels are associated with 
the severity of behavioral symptoms in ASD [39]. It was also 
reported that the expression of zonulin was associated with 
specific strains of the gut microbiota, such as Faecalibacte-
rium and Ruminococcaceae [40]. Taken together, the results 
suggest that the gut microbiota affects intestinal permeabil-
ity, and that the triggered inflammatory processes contrib-
ute to the pathogenesis of ASD.
CHANGES IN GUT MICROBIOTA 
COMPOSITION IN ASD 
Many cross-sectional studies have shown alterations in 
the composition of microbiota in ASD. Common findings in 
many studies include increased Firmicutes to Bacteroidetes 
ratio and a higher abundance of Clostridium in ASD. 
Metagenomic analysis carried out by Williams et al. [41] 
showed compositional dysbiosis manifests as a decrease in 
Bacteroidetes, an increase in the ratio of Firmicutes to Bacte-
roidetes, and an increase in Betaproteobacteria in ASD pa-
tients. Tomova et al. [42] reported that children with autism 
showed a significant increase in the Firmicutes to Bacteroide-
tes ratio and elevation of the amount of Lactobacillus spp. 
Strati et al. [43] revealed that a significant increase in the Fir-
micutes/Bacteroidetes ratio in ASD patients was associated 
with a decrease in Bacteroidetes. They also found a decrease 
in the abundance of Alistipes, Bilophila, and Veillonella, but a 
significant increase in the abundance of Collinsella, Coryne-
bacterium, and Lactobacillus in the ASD group. In the case 
of Clostridium, more species of this genus were found in the 
feces of children with autism than in normal children, and 
counts were also higher in children with autism [44]. Clos-
tridium boltae and cluster I and XI were found to be several 
times more abundant in children with autism than in nor-
mal children [45]. Recently, Alshammari et al. [46] revealed 
that the incidence of Clostridium perfringens was signifi-
cantly higher in an ASD group than in a control group. 
However, these findings are not always consistent between 
studies. In contrast to the finding that the Firmicutes to Bac-
teroidetes ratio increased due to a reduction in Bacteroidetes, 
De Angelis et al. [47] found that levels of Bacteroidetes and 
some Alistipes and Akkermansia species were higher in chil-
dren with ASD than in normal children.
In addition, heterogeneous results have been reported. Fae-
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calibacterium, Ruminococcus, and Bifidobacterium were rela-
tively less abundant, whereas Caloramator, Sarcina, Sutterel-
laceae, and Enterobacteriaceae were more abundant in 
children with ASD than in normal children and children 
with Pervasive Developmental Disorder Not Otherwise Spec-
ified (PDD-NOS) [47]. Kang et al. [48] reported significantly 
lower abundances of the genera Prevotella, Coprococcus, and 
unclassified Veillonellaceae in samples from individuals with 
autism than in samples from neurotypical children. In-
creased Bacteroidaceae, Prevotellaceae, and Ruminococcaceae 
[49], and reduced Prevotella copri, Faecalibacterium prausnit-
zii, and Haemophilus parainfluenzae [50] were also found in 
the ASD population.
There have been several studies using non-autistic siblings 
as controls. Tomova et al. [42] reported that Desulfovibrio, 
Bifidobacterium, and Clostridia were more abundant in the 
ASD group, while Lactobacillus was relatively abundant in 
siblings. Furthermore, regarding measurements of abun-
dance of Bacteriodetes and Firmicutes, the sibling groups 
tended to fall somewhere between those of normal children 
with no family history of ASD and those of children with 
ASD. This finding suggests that the pattern of microbial 
composition can be an indicator of the disease burden of 
ASD. However, contradictory results have also been report-
ed. Several studies have compared microbial composition 
between children with ASD and neurotypical siblings and 
revealed no difference between the two groups [51-53]. These 
results suggest that the microbial composition was formed 
only under the influence of shared environmental factors, 
including eating habits.
There have been associations between abundance of cer-
tain microbial strains and the severity of ASD symptoms re-
ported. The level of Clostridium abundance has been corre-
lated with the disease severity of ASD, as measured using the 
Childhood Autism Rating score [23], and children with ASD 
with more severe symptoms have been shown to have higher 
levels of Desulfovibrio and Clostridia than children with 
milder symptoms [42]. A recent study also revealed that 
abundance of Megamonas was positively correlated with Au-
tism Behavior Checklist scores [54].
Intestinal tissue obtained through biopsy has been used to 
confirm the composition of microorganisms present in some 
cases. Williams et al. [55] found that the genus Sutterella, 
which is rare in normal individuals, was abundant in ileum 
and caecum tissues of ASD patients. Kushak et al. [56] com-
pared microbial composition between ASD patients and 
normal groups using duodenal mucosa tissue. The Burkhold-
eria genus was more abundant in ASD patients than in nor-
mal controls, while levels of bacteria belonging to the Neiser-
ria genus were relatively low. No findings in these studies 
were found to be consistent with the results obtained from 
stool sample-based studies. This discrepancy may be because 
the stool sample reflects the microbial composition in the 
large intestine, while the duodenal mucosa reflects the mi-
crobial composition in the small intestine [57]. Given this 
discrepancy, some researchers argue that samples represent-
ing the entire population of bacteria in the gut are required 
for further study [58].
As mentioned above, there are several studies showing 
differences in the intestinal microbial composition between 
the normal population and ASD patients. However, most of 
the studies included only a small number of subjects, and 
variables such as diet were not thoroughly controlled for [59]. 
As a result, the pattern of microbial composition has not yet 
been established as an ASD endophenotype. Nevertheless, it 
is clear that changes in microbial composition occur in the 
gut of ASD patients. In particular, some studies have found a 
correlation between symptom severity and specific strains, 
suggesting that there may be a correlation between ASD de-
velopment and the gut microbiota.
ASSOCIATION BETWEEN THE 
GUT MICROBIOTA AND 
ASD-RELEVANT BEHAVIORS 
Animal-based research to date has helped us better under-
stand the role gut microbiota plays in ASD (Table 1). Lack of 
social behavior, the most important feature of ASD, has been 
observed in mice with altered gut microbiota, including GF 
mice. GF mice show decreased propensity to interact with a 
novel partner versus a nonsocial object or familiar partner in 
the three-chambered sociability test, and they spend more 
time exploring an empty chamber than a chamber with a 
novel mouse [60]. Stilling et al. [61] reported that a group of 
GF mice showed significantly lower interaction with other 
mice than controls and post-weaning colonized mice. In the 
other study, GF mice were found to spend significantly more 
time sniffing and interacting with a novel stimulus, due to 
higher motor activity than that in conventionally raised 
mice [62]. The results of these studies seem contradictory, 
but the conclusions are similar in that the role of the gut mi-
crobiota in the development of social behavior is important. 
In addition, GF mice also show increased stereotyped self-
grooming behavior and mice with an altered gut microbiota 
display repetitive burying behavior, as measured by the mar-
ble-burying test [37,60]. In some studies, GF mice have ex-
hibited increased locomotor activity, rearing behaviors [63], 
and decreased anxiety-like behavior [62,64,65]. Moreover, 
many of these ASD-like behaviors have been reversed upon 
colonization with the gut microbiota in healthy mice [63,66].
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Table 1. Animal studies about Microbiota and ASD-like phenotypes
Study Country Subject Behavior Group Description
Sudo et al. 
  [158]
Japan Mice Stress  
  response
Germ free/ 
  Specific pathogen free/  
  Gnotobiotic mice 
Germfree mice have elevated stress  
  response, reduced BDNF in cortex and  
  hippocampus. Germfree colonization  
  with Bifidobacterium infantis reversed  
  hypothalamic-pituitary-adrenal stress  
  response
Verdú et al. 
  [159]
Canada Mice Visceral  
  hypersensitivity
Groups treated with  
  Antibiotic and Lactobacillus 
  paracasei, Antibiotic or  
  Placebo (saline water)
L. paracasei NCC2461 normalized  
  visceral sensitivity
Desbonnet 
  et al. [141]
Ireland Rats Depression- 
  like behavior
Groups treated with  
  Bifidobacteria  
  infantis or not
Probiotic B. infantis treatment did not  
  change swimming, climbing, and  
  immobility but decreased IFNγ,  
  TNFα and IL-6 cytokines
Desbonnet  
  et al. [142]
Ireland Rats Depression- 
  like behavior
Maternal separation stress  
  models treated with B.  
  infantis, citalopram or not
Probiotic Bifidobacterium infantis  
  treatment in a maternal separation  
  stress model normalized IL-6 levels,  
  increased swim behavior and reduced  
  immobility in forced swim test, and  
  restored basal noradrenaline levels  
  in brainstem
McKernan 
  et al. [160]
Ireland Rats Visceral  
  hypersensitivity
Visceral normosensitive   
  (Sprague-Dawley) and  
  visceral hypersensitive  
  (Wistar-Kyoto) rat
Probiotic Bifidobacterium infantis 35624  
  reduces visceral pain
Bercik et al. 
  [161]
Canada Mice Anxiety- 
  like behavior
Uninfected control and  
  T muris-infected mice,  
  treated with placebo,  
  etanercept, budesonide,  
  and probiotics
Colonic inflammation induced anxiety like  
  behavior, decreased hippocampal BDNF  
  mRNA, and increased circulating TNF-α  
  and IFNγ Probiotic Bifidobacterium  
  longum restored behavior and BDNF
Messaoudi 
  et al. [145]
France Rats and  
  adults 
Anxiety,  
  depression,  
  and stress
Groups treated with  
  probiotic preparation,  
  placebo (0.5%  
  methylcellulose  
  solution) and diazepam
Probiotic (Lactobacillus helveticus and  
  Bifidobacterium longum) reduced  
  anxiety-like behavior in rats and reduced  
  psychological stress inpatients
Diaz Heijtz 
  et al. [63]
Sweden Mice Motor activity  
  and anxiety- 
  like behavior
Germ free/Specific  
  pathogen free
Germ-free mice have increased motor  
  activity and decreased anxiety  
  Changes in PSD-95 and synaptophysin  
  expression in striatum
Bravo et al. 
  [162]
Canada Mice Anxiety- and  
  depression-related  
  behaviors
Lactobacillus rhamnosus  
  (JB-1)-fed mice
  Broth-fed mice (control)
Probiotic L. rhamnosus treatment of mice  
  in a stress model reduced stress and  
  increased GABA receptor expression in  
  prefrontal cortex. L. rhamnosus increased  
  cortical GABA (B1b) receptor expression,  
  decreased GABA (Aα2) expression in  
  prefrontal cortex and amygdala,  
  but increased in hippocampus.  
  L.rhamnosus reduced stress, anxiety and  
  depression behavior
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Hsiao et al. [37] reported that offspring from an immune-
activated mother showed changes in gut microbial composi-
tion. These offspring were found to not only have GI barrier 
defects, but also multiple ASD-related endophenotypes in-
cluding impairments of social interaction and communica-
tion. Treatment with human commensal Bacteroides fragilis 
ameliorates many of these ASD-related behaviors. Buffington 
et al. [67] found that offspring from high-fat diet mother rats 
exhibited social skill deficits, which was associated with gut 
microbial dysbiosis. They concluded that abnormalities in the 
gut microbiota cause oxytocin deficiency, resulting in insuffi-
cient long-term potentiation (LTP) in the ventral tegmental 
area and defects in social behavior. Similar to the study of 
Hsiao et al. [37] this behavioral problem was restored by colo-
nization with a single strain of bacteria, Lactobacillus reuteri. 
A recent study conducted by Sharon et al. [68] showed that 
transplanting the gut microbiota from human donors with 
ASD into GF wild type mice induced behavioral deficits rele-
vant to ASD. Mice colonized with samples of ASD donors dis-
played more repetitive behavior, less locomotion, and less 
communication than did mice colonized with samples of typi-
cally developed (TD) donors. The study also reported differ-
ential gene expression profiles in the prefrontal cortex and 
striatum, which is known to mediate social behavior between 
mice with ASD microbiota and mice with microbiota of TD 
donors, due to extensive alternative splicing of risk genes in 
the brains of mice with ASD microbiota. As previous studies 
have shown that alternative splicing occurs in the brain of hu-
mans with ASD, these findings suggest that the gut microbiota 
plays an important role in the occurrence of ASD, via altering 
the pattern of brain development. Metagenomic analysis 
showed that mice with ASD microbiota were relatively defi-
cient in 5-aminovaleric acid (5AV) and taurine. BTBR 
T+Itpr3tf/J mice showing ASD features ingested solutions 
containing 5AV and taurine, which resulted in an improve-
ment in ASD-like behavior.
The amygdala, another key region involved in social in-
teraction, has also been repeatedly reported to be affected 
by microbiota. Examination of the amygdala in GF mice, 
before and after colonization with microbiota, showed sig-
nificant differences in gene expression, exon usage, and 
RNA editing [69]. This also revealed that different tran-
scriptional processes are activated in response to social 
stimuli in control and GF mice [61]. 
Table 1. Animal studies about Microbiota and ASD-like phenotypes (continued)
Study Country Subject Behavior Group Description
Bercik et al. 
  [163]
Canada Mice Anxiety-like behavior Dextran sodium sulfate  
  colitis with Bifidobacterium 
  longum or control medium
Chemical colitis mouse model treated  
  with probiotic (B. longum) had normalized  
  anxiety like behavior. Chronic colitis model  
  has increased anxiety. B. longum normali 
  zed behavior, but no change in BDNF  
  expression
Hsiao et al. 
  [37]
USA Mice ASD-like behaviors MIA offspring treated  
  with vehicle or  
  Bacteroides fragilis
MIA mice have decreased GI barrier,  
  increased IL-6, decreased cytokine/ 
  chemokine, and gut microbial dysbiosis,  
  and autism-related behaviors that were  
  restored following colonization with B.fragilis
Desbonnet 
  et al. [66]
Ireland Mice Social preference  
  and repetitive  
  behaviors
Germ free rearing  
  and germ-free  
  bacterial colonization  
  mice groups
Germ free mice had deficits in social  
  avoidance, social novelty, social  
  investigation and also had increased  
  repetitive self-grooming
Buffington 
  et al. [67]
USA Mice Social behavior Maternal high fat diet  
  treated with Lactobacillus  
  reuteri or not
Maternal high fat diet induced social  
  deficits in offspring are restored following  
  colonization with Lactobacillus reuteri
Sharon et al. 
  [68]
USA Mice Social behavior  
  and repetitive  
  behaviors
Mice colonized by feces  
  of human donors  
  with ASD or TD donor
Mice with human ASD, but not TD  
  displayed ASD-like behaviors Extensive  
  alternative splicing of risk genes are  
  observed in brains of mice with ASD.  
  Metabolome analysis showed significant  
  differences between the two groups
ASD: autism spectrum disorder, BDNF: brain derived neurotrophic factor, TNF-α: tumor necrosis factor-α , IL: interleukin , GABA: 
gamma-amino-butyric acid, MIA: maternal immune activation, GI: gastrointestinal, TD: typically developed
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METABOLITES INDUCED BY THE GUT 
MICROBIOTA IN ASD
The gut microbiota are known to modulate the CNS by 
transmitting molecular signals in a variety of ways [2]. Short-
chain fatty acids (SCFA), representative signaling molecules, 
are the product of food fermentation by the gut microbiota 
[70,71]. SCFA affect the brain by passing through the BBB, 
entering the brain, and regulating the production of neu-
rotransmitters such as serotonin and dopamine [47]. In addi-
tion, SCFA are known to be involved in immune action by 
regulating T-cell cytokine secretion [72]. In ASD patients, the 
total amount of SCFA is lower than in TD subjects, and the 
amount positively correlates with Faecalibacterium, Rumino-
coccus, and Bifidobacterium. Butyrate, in particular, shows a 
significant decrease, while propionate is found to be higher 
than in TD subjects [47]. Although propionate is known to 
prevent damage to the body from hypertension by inhibiting 
excessive activity of immune cells [73], elevated levels can 
have disruptive effects [74]. Case reports have shown that in-
creased propionate blood levels can cause behavior problems 
similar to autism [75], and propionacemia has been identified 
in children with autism [76]. Propionate can act as a neuro-
toxin that inhibits the formation of Nicotinamide adenine 
dinucleotide (NADH). Since NADH is a major substrate of 
the electron transport chain, it eventually degrades the ner-
vous system [77]. Indeed, male rats injected with propionate 
into their brains displayed behavioral problems such as social 
behavior impairments and neuroinflammatory responses 
similar to those seen in ASD [78]. Peripheral propionate in-
jections in rats also induce anxiety-like behavior and impair 
social interaction [79]. In addition, propionate adminsistered 
prenatally by maternal injection of sodium propionate solu-
tion promotes several behavioral problems associated with 
ASD in offspring [80]. Patients with Rett syndrome, a repre-
sentative genetic cause of ASD, also show higher propionate 
levels than normal subjects [81]. In addition, Clostridia spe-
cies, previously mentioned to be more abundant in ASD pa-
tients, are known to be involved in the production of propio-
nate [43]. 
Butyrate, on the other hand, is a major SCFA that has neu-
roprotective effects, and is the main source for energy me-
tabolism in intestinal epithelial cells, especially colonocytes 
[82]. As the most potent promoter of intestinal regulatory T 
cells, it mediates the inflammatory response in the colon, 
and has the prophylactic and therapeutic potential to prevent 
ulcerative colitis and colorectal cancer [83]. It also prevents 
inflammatory reactions by regulating the production of anti-
inflammatory cytokines such as interleukin (IL)-10 [84]. The 
anti-inflammatory action of butyrate also occurs in the 
brain [85]. In fact, butyrate is known to attenuate the symp-
toms of some neurodegenerative diseases [86]. The role of 
butyrate in ASD has not been fully studied, but given its 
neuroprotective function, it is possible that reduced butyrate 
may affect the pathophysiology of ASD.
Lipopolysaccharide (LPS) is a type of endotoxin produced 
by gram-negative bacteria, which promotes the secretion of 
pro-inflammatory cytokines, nitric oxide, and eicosanoids 
[87]. It can induce disruption of the BBB and increase BBB 
permeability, allowing exotoxins such as metals to enter the 
brain, which eventually accumulate in the brain and promote 
inflammatory responses through the activation of microglia 
[88]. Some studies showed that prenatal exposure to LPS by 
gram-negative bacterial infection induces autism-like behav-
iors, including social skill deficits [89,90]. Custódio et al. [91] 
conducted a study to determine which behavioral problems 
are caused by LPS exposure during the neonatal period in 
mice. Male mice injected with LPS solution at postnatal days 
5 and 7 exhibited anxiety-like and repetitive behaviors during 
tasks. LPS-challenged male mice also showed increased im-
mune activity, as measured by levels of IL-4 and IL-6 in the 
prefrontal lobe, hippocampus, and hypothalamus. These 
findings suggest that ASD features may occur if an immune 
reaction is triggered by changes in the gut microbiota or bac-
terial infection early in life. Similarly, a recent study revealed 
that early life immune system activation triggered by LPS 
lead to increased social impairment and repetitive behavior 
in mice [92]. In both studies, these changes were prominent 
in male rats, consistent with male predominance in ASD 
prevalence.
P-cresol is a substance formed by bacteria, which acts as a 
toxin in various metabolic processes in humans [47], and is 
associated with abnormalities in the nervous system, such 
as increased lipid peroxidation in the brain, decreased 
Na(+)-K+ ATPase activity, and inhibition of noradrenaline 
formation [93,94]. A representative bacterium known to 
form p-cresol is Clostridium difficile. C. difficile stimulates 
the expression of the enzyme p-hydroxyphenylacetate (p-
HPA) and consequently induces the fermentation of tyro-
sine for the formation of p-cresol. Bacteria such as Clostridi-
um scatologenes, Lactobacillus, and Pseudomonas contribute 
to the conversion of toluene to p-cresol [95], and this was 
found to be higher in fecal and urine samples of ASD pa-
tients than in normal subjects [47,96,97]. Considering that 
urinary p-cresol is correlated with the severity of autism 
symptoms [98], it is thought to contribute to the worsening 
of ASD symptoms and gut dysfunction [99]. 
In addition, some strains directly affect the brain by being 
involved in the formation of neurotransmitters. Serotonin is 
known to be involved in critical stages such as neuronal dif-
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ferentiation or migration, myelination, and synaptic forma-
tion during the development of the CNS [100]. Serotonin 
produced by enterochromaffin cells is stored in the epitheli-
um and nerve cells of the intestinal barrier [101]. At this 
time, serotonin reuptake transporter regulates serotonin ac-
tivity by transferring secreted serotonin within the synapse 
back into the cell. Male GF mice have a significant elevation 
of 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic 
acid levels (5-HIAA) in the hippocampus [64], which are the 
main metabolites of the tryptophan metabolic pathway [102]. 
Another study also found that GF mice had increased 5-HT 
levels in the hippocampus and increased tryptophan levels 
in the blood [103]. Given that ASD-relevant endophenotypes 
such as social skill deficits and cognitive rigidity have been 
found in rodents with deficits in the 5-HT system [104-106], 
serotonin may be a neurotransmitter that plays an important 
role in the pathophysiology of ASD. Indeed, it has been 
shown that hyperserotoninemia occurs in autism [107]. Data 
reported by neuroimaging and post-mortem studies also 
suggest abnormalities in the brain serotonergic system in 
ASD [108,109]. Clostridia species promote the conversion of 
tryptophan to 5-HT by increasing the mRNA levels of tryp-
tophan hydroxylase 1 in endochromaffin cells [110]. Species 
involved in serotonin production include Peptostreptococcus 
russellii, Lactobacillus [111-113], Streptococcus, Escherichia 
and Enterococcus [114]. Considering this fact, the gut micro-
biota may be the link between ASD and serotonin abnor-
mality that is not yet fully understood.
ALTERED IMMUNE RESPONSE IN ASD 
AND THE GUT MICROBIOTA 
As mentioned earlier, abnormalities in various immune 
responses have been observed in ASD patients. In terms of 
neuroimmunity, extensive microglial activity was observed 
in the brain tissue of ASD patients, including cortical re-
gions, white matter, and cerebellum [34]. It was also found 
that the density of reactive microglia was increased in the 
dorsolateral prefrontal cortex of ASD patients [115]. The in-
creased expression of microglial marker genes including 
triggering receptor expressed on myeloid cells 2 (TREM2) 
and killer cell activating receptor-associated protein (DAP12/
KARAP) in the prefrontal cortex of ASD patients also sug-
gests a dysfunction of neuroimmunity in ASD [116]. These 
neuroimmune abnormalities were also confirmed in animal 
models, especially in the maternal immune activation (MIA) 
model, which is known to be associated with the develop-
ment of ASD [117,118]. When the maternal immune system 
was stimulated by the administration of LPS during the ges-
tational period, changes in microglial receptor function, 
dysregulated immune response, and ASD-relevant behaviors 
were observed in male offspring mice [37,119]. 
Various systemic immune abnormalities have been also 
observed in ASD. Changes in this cytokine network have 
been reported in the CSF and post-mortem brain tissue of 
ASD patients [34]. In particular, recent studies support the 
possibility that abnormalities in pro-inflammatory cyto-
kines, including IL-6 and TNF-α, may affect the develop-
ment of ASD. IL-6 is a cytokine produced by microglia, as-
trocytes, and neurons, and is necessary for neuron survival. 
However, prolonged elevation of IL-6 levels may induce sev-
eral pathologies in the brain [120]. One study found that 
overexpression of IL-6 caused problems with adhesion and 
migration of neuronal cells, and eventually facilitated the 
formation of excitatory synapses [121]. Animal model stud-
ies have confirmed that these changes can lead to ASD-rele-
vant behavior [122]. Conversely, administration of anti-in-
flammatory agents in autistic mice have been found to 
reduce IL-6 levels, thereby reducing autism-like behavior 
[123]. TNF-α is a molecule that is involved in synaptic plas-
ticity [124]. Long-term elevation of TNF-α is known to in-
hibit LTP of the synapse and induce the learning and memo-
ry problems that are observed in ASD [125]. The CSF to 
serum ratio of TNF-α is increased in ASD patients [126]. As 
a result of analyzing the brain tissue of ASD patients, it was 
confirmed that the level of TNF-α was higher than that in 
TD subjects, specifically in the frontal cortex [127]. In addi-
tion, several studies have reported elevation of IL-1β levels, 
another immunomodulatory molecule involved in the inhi-
bition of LTP and the reduction of synaptic strength [128], in 
peripheral blood of ASD patients [129,130]. These findings in 
ASD patients suggest that neurotoxicity or inhibition of neu-
rodevelopment caused by immune abnormalities could be 
key pathophysiologies of ASD.
Several studies have shown that immune system abnormali-
ties in ASD patients are associated with the gut microbiota. 
Higher density and branching complexity of microglia in 
multiple brain regions were observed in GF mice than in mice 
raised in a specific pathogen free environment. Similar to GF 
mice, microglial density was increased in mice colonized with 
a less complex composition of the gut microbiota. GF mice 
with malformed microglia showed social avoidance and a re-
duced immune response against stimuli such as viral infec-
tion. In the same study, both microglia abnormalities and 
ASD-relevant behaviors were corrected after re-colonization 
of GF mice with the gut microbiota extracted from TD mice 
[131]. Specific bacterial species from the gut microbiota, such 
as Bacteroides fragilis and a Clostridia species, are known to 
modulate immune reaction by upregulating levels of IL-
10-producing T regulatory cells [132]. Interaction between the 
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gut microbiota and the immune system could be relevant to 
the immune dysregulation found in ASD. For example, regu-
latory T-cell and T helper cell abnormalities are observed in 
ASD patients [127]. Considering that the microbiota is in-
volved in the differentiation of myeloid cells, the monocyte 
and macrophage abnormalities observed in peripheral blood 
of ASD patients are also thought to be related to the gut mi-
crobiota [133,134]. 
MIA during pregnancy is considered to increase the risk 
for ASD [117,135]. As mentioned above, Hsiao et al. [37] re-
vealed offspring from MIA mice displayed not only ASD-
relevant features, such as anxiety-like behavior, stereotypy, 
and reduced sociability, but also dysbiosis of the gut micro-
biota. Moreover, MIA offspring showed a change in gut per-
meability when compared to control mice due to decreased 
expression of tight junction proteins, as well as the altered 
expression of cytokines such as IL-12. In this study, restora-
tion of the gut microbiota by oral treatment with specific 
bacterial species not only corrected gut permeability, but 
also improved behavioral problems similar to ASD. A recent 
study found that less ASD-relevant behaviors were observed 
in offspring from MIA mice with preconception microbiota 
transplantation than in offspring born to conventional MIA 
mice. The authors found that changes in microbial composi-
tion caused changes in IL-17a secretion, and also confirmed 
that inhibition of IL-17a signaling could lead to amelioration 
of ASD phenotypes, such as social impairment [136]. Collec-
tively, these findings clearly indicate that the gut microbiota 
contributes to the immunological abnormalities observed in 
ASD. Furthermore, there is a potential for the gut microbiota 
to act as a link between MIA and the pathogenesis of neuro-
developmental disorders, including ASD. Further studies are 
needed to investigate the effects of microbiota on the im-
mune system in order to uncover the pathophysiology of 
ASD, which is still unclear.
THERAPEUTIC APPROACHES VIA THE 
GUT MICROBIOTA FOR ASD
Probiotics generally refers to a collection of living microor-
ganisms known to provide health benefits by improving or 
restoring the composition of the intestinal microflora [137]. 
The mechanism is still unknown, but a predominant role of 
probiotics is to modulate the immune system [138]. For ex-
ample, Lim et al. [139] found that certain strains of Weissella 
cibaria in kimchi improved the symptoms of atopic dermati-
tis by regulating the response of regulatory T cells. In addi-
tion, probiotics play a beneficial role in strengthening the 
barrier, participating in the formation of nutrients such as vi-
tamins, and preventing the growth of pathogens [33,137]. 
Various probiotics have been studied in neurological and 
psychiatric disorders, among which the most beneficial 
strains are Bifidobacterium and Lactobacillus [140]. Bifido-
bacterium infantis improved not only the behavioral deficit of 
rat pups separated from their mother, but also physiologic re-
sponses including normalizing IL-6 and tryptophan release 
[141,142]. Innately anxious male mice, which were fed with 
Bifidobacterium longum and Bifidobacterium breve, showed 
reduced anxiety in behavioral tasks such as the marble-bury-
ing test [143]. Janik et al. [144] used non-invasive magnetic 
resonance spectroscopy techniques to observe what hap-
pened in the brain of mice when Lactobacillus strains were 
administered. As a result, brain concentrations of biomarkers 
such as glutamate, N-acetyl aspartate, and GABA were in-
creased. In humans, urinary free cortisol was decreased with 
treatment by probiotics consisting of Lactobacillus helveticus 
and Bifidobacterium longum [145]. Lactobacillus casei Shirota 
improves stress-related GI symptoms and psychological dis-
tress [146]. As mentioned above, colonization with strains 
such as Lactobacillus reuteri and Bacteroides fragilis has been 
shown to improve the behavior of mice showing an ASD phe-
notype [37,67]. In addition to these findings, Grossi et al. [147] 
reported a case of an ASD child whose symptoms had been 
improved through the use of probiotics. The subject was a 12 
year-old boy with ASD and severe cognitive disability. Taking 
probiotics containing Bifidobacterium breve, B. longum, B. 
infanti, Lactobacillus acidophilus, L. plantarum, L. paracasei, 
L. bulgaricus, and L. delbrueckii for 3 months led to better so-
cial affects, as measured by the Autism Diagnostic Observa-
tion Schedule. The improvement lasted up to 9 months after 
discontinuation of treatment. Niu et al. [148] applied a com-
bination of applied behavior analysis (ABA) training and 
probiotic administration for 4 weeks in children with ASD. 
Although it was difficult to distinguish from the effects of 
ABA, the results showed that the symptoms of ASD patients 
taking probiotics, as measured by the Autism Treatment 
Evaluation Checklist, improved. These findings suggest that 
probiotics could be used to treat ASD, even though it would 
be too premature to conclude this, due to several limitations. 
Fecal microbiota transplantation (FMT) is being actively 
studied as a new treatment for many diseases in which the 
gut microbiota is known to contribute to pathophysiology. 
Unlike probiotics, which administer to some specific 
strains, FMT alters the composition of hundreds of strains 
through the transplantation of feces of healthy donors into 
the intestines of patient [149]. FMT is recognized as a stan-
dard treatment for repeated infection of Clostridium difficile 
[150], and has been studied as a treatment tool for various 
diseases such as ulcerative colitis [151], Crohn’s disease [152], 
irritable bowel syndrome [153], and epilepsy [154]. Kang et 
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al. [155] conducted a study to identify the therapeutic effect 
of FMT in 18 children with ASD. The treatment protocol 
was divided into four stages. Children were given vancomy-
cin for two weeks and bowel cleansing prior to transplanta-
tion. Standardized Human Gut Microbiota was adminis-
tered orally and rectally, with a high initial dose for 2 days 
and a lower maintenance oral dose, alongside a stomach 
acid suppressant, for 7–8 weeks. Symptoms, as rated by the 
Gastrointestinal Symptom Rating Scale, were an approxi-
mately 80% reduced at the end of treatment, and included 
significant improvements in constipation, diarrhea, and ab-
dominal pain. Overall autism symptoms, as measured by 
Parental Global Impression III, were also improved, and the 
effect was maintained for 8 weeks after discontinuation of 
treatment. Bacterial changes after FMT include increased 
diversity and altered abundance of three genera, Bifidobac-
terium, Prevotella, and Desulfovibrio. Recently, the same au-
thors published a follow-up study of 18 FMT patients, which 
showed improvement in symptoms as long as 2 years after 
the end of treatment [156]. Although the number of partici-
pants was small, these findings suggest that FMT can be a 
useful therapeutic tool for ASD. The use of whole feces can 
lead to transferring pathogens from the donor to the pa-
tient, causing an unexpected infection. Attempts are made 
to reduce the possibility of unexpected infections by screen-
ing donors using stringent criteria, but there are always 
risks [157]. 
CONCLUSION 
The microbiota is considered to play an essential role in 
the development of the normal nervous system and mainte-
nance of brain function. Considering the results of various 
animal studies and human studies, it is clear that ASD and 
the gut microbiota are closely related. 
First, the incidence of GI disturbances is higher in ASD 
patients than in normal subjects [15]. The results of several 
studies show a positive correlation between the severity of 
GI symptoms and core symptoms of ASD including social 
skill deficits [21,22]. These results suggest that core symp-
toms and GI disturbances may share the same pathology. 
The gut microbiota is thought to contribute to this process 
by altering the integrity of barriers, increasing permeability, 
and consequently inducing inflammation.
Several studies have attempted to confirm changes in mi-
crobial compositions in the ASD population. As a result of 
these efforts, several common findings have emerged, in-
cluding a reduction in overall microbial diversity, an increase 
in Firmicutes to Bacteroidetes ratio [41-43], and a relative 
abundance of Clostridium [44-46]. However, many of these 
studies have limitations. Despite the high likelihood of bias 
when considering the properties of the gut microbiota that 
are sensitive to diet, most researchers have not found a way 
to control the variables of diet. In addition, most studies 
were carried out with a relatively small number of subjects, 
making it difficult to generalize the results. Many studies 
adopted a cross-sectional design, which makes it difficult to 
determine the causal relationship between alteration of the 
gut microbiota and disease development or course [59]. Fu-
ture work should focus on overcoming these limitations.
Animal studies provide relatively more information about 
the relationship between ASD and the gut microbiota. In 
particular, studies showed that behavior is normalized by 
re-colonization with specific strains in offspring mice with 
ASD phenotype, suggesting the possibility that the gut mi-
crobiota can be used therapeutically [37,67]. Moreover, re-
cent studies have shown that mice transplanted with stools 
of ASD patients exhibit ASD-like behaviors accompanied 
by changes in gene expression in the brain, unlike mice 
transplanted with normal stools [68]. These findings bring 
us a step closer to understanding the role of the gut micro-
biota in the development of ASD, which has not been possi-
ble through human studies.
Several metabolites produced by the gut microbiota have 
also been studied. Overall SCFA levels in ASD patients are 
reduced, while propionate, which could act as an endotoxin, 
is increased [47]. Animal studies have shown that exposure 
to propionate and LPS may cause behavioral problems simi-
lar to ASD, and changes in immune activity [78,91]. Sero-
tonin metabolic abnormalities have been observed in ASD 
patients [107-109], and there is a possibility that the gut mi-
crobiota may be involved in this process [110]. Continuing 
the search for metabolites will make it possible to identify 
the missing link between the gut microbiota and ASD. 
Immune abnormalities have been considered to play an 
important role in the pathogenesis of ASD through several 
recent studies. In the brain tissue of ASD patients, changes 
in reactivity as well as morphological changes in microglia 
and astrocytes have been observed. In addition, alteration of 
various cytokine levels, including IL-6 and TNF-a, has been 
also observed in ASD patients. It is possible that these abnor-
mal immune responses interfere with brain functions such 
as learning and memory and contribute to the development 
of ASD. Several studies support the link between changes in 
the immune response and the gut microbiota in ASD. In 
particular, studies using the MIA mouse model confirmed 
that various deficits in the offspring of MIA mice, including 
ASD-relevant behaviors and changes in gut permeability, 
were improved through correction of the gut microbiota. 
These findings indicate that the interaction between micro-
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biota and the immune system may play an important role in 
the pathogenesis of ASD.
Based on the results of the studies mentioned, studies were 
conducted to confirm the effectiveness of the therapeutic 
tools using microbiota. There have been no large, well-de-
signed studies as yet, but some of the findings provide us with 
a positive impression regarding the therapeutic use of micro-
biota. In particular, we should note that the results of the 
study showed that FMT improved the symptoms in 18 chil-
dren with ASD [155,156]. However, it must be recognized that 
FMT also presents a concurrent risk of infection. 
In conclusion, we suggest that the gut microbiota is deeply 
involved in the development of ASD. However, more research 
is needed to further explore the development of ASD based 
on the microbiota-gut-brain axis. Greater control over vari-
ables such as diet and drug use will be particularly important 
for reducing the possibility of bias in human studies. We hope 
that our review, which encompasses many studies conducted 
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